Actively Recruiting

Early Phase 1
Age: 18Years +
All Genders
NCT04048278

Lidocaine Infusion in Pancreatic Cancer

Led by University of Illinois at Chicago · Updated on 2025-03-03

46

Participants Needed

1

Research Sites

373 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study elucidates the effects of the intravenous (IV) lidocaine infusion on the biology of pancreatic circulating tumor cells (CTCs) isolated from patients undergoing robotic pancreatectomy for all types of pancreatic cancer. A prospective randomized controlled double blinded trial design will be used for the proposed study.

CONDITIONS

Official Title

Lidocaine Infusion in Pancreatic Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Histologically or cytologically confirmed resectable adenocarcinoma or other pancreatic cancers
  • Has at least one measurable tumor
  • Patients found to have metastatic disease during initial surgical exploration
  • Has read, understood, and signed informed consent approved by IRB/IEC
  • Prior systemic treatments for metastatic disease allowed, including targeted therapies and chemotherapy
Not Eligible

You will not qualify if you...

  • American Society of Anesthesiologists (ASA) physical status greater than 3
  • Allergy or hypersensitivity to amide-linked local anesthetics
  • Second or third degree heart block
  • Severe sinoatrial block
  • Current treatment with class I antiarrhythmic drugs: quinidine, flecainide, disopyramide, or procainamide
  • Previous treatment with amiodarone
  • Adams-Stoke syndrome
  • Wolff-Parkinson-White syndrome
  • History of blood clots, pulmonary embolism, or deep vein thrombosis unless controlled with anticoagulants
  • Known HIV positivity or untreated/uncontrolled hepatitis B or C

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Illnois at Chicago

Chicago, Illinois, United States, 60612

Actively Recruiting

Loading map...

Research Team

A

Alexandra Barabanova, MS

CONTACT

G

Gina E. Votta-Velis, MD PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here